Clinigen Group PLC | Mutual Funds

Mutual Funds that own Clinigen Group PLC

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
AXA Framlington UK Select Opportunities Fund
8,000,000
6.54%
0
2.61%
03/15/2018
Old Mutual Invt. Funds Series I - UK Smaller Cos. Fund
3,016,000
2.47%
-95,000
2.44%
07/31/2017
Neuberger Berman International Equity Fund
2,089,090
1.71%
96,941
1.22%
06/30/2018
Henderson Smaller Companies Investment Trust Plc
1,919,659
1.57%
-1
2.41%
12/31/2017
CPR Silver Age
1,783,215
1.46%
1,783,215
1.07%
12/29/2017
GVO Investment Funds (Dublin) Plc - UK Focus Fund
1,598,234
1.31%
360,204
4.44%
06/30/2017
Invesco Perpetual Sm. Cos. & Mkts Invt. Ser-UK Sm. Cos. Eq.
1,589,187
1.3%
102,339
2.27%
03/29/2018
1,397,877
1.13%
0
2.34%
07/31/2018
Putnam Global Health Care Fund
1,382,802
1.12%
0
1.26%
06/30/2018
Strategic Equity Capital Plc (Top 10 Holdings)
1,381,165
1.12%
-147,987
7.72%
03/31/2018

About Clinigen Group

View Profile
Address
Pitcairn House
Burton-on-Trent Staffordshire DE14 2WW
United Kingdom
Employees -
Website http://clinigen.co.uk
Updated 07/08/2019
Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA), Clinigen Specialty Pharmaceuticals (SP), and Link Health Care. The Clinigen CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies.